
CDC Advisory Committee on Immunization Practices Recommends Nirsevimab-alip to Prevent RSV in Infants
CDC Advisory Committee on Immunization Practices voted 10 to 0 to recommend the routine use of nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants.





























